Science

BiXAb® Platform Technologies

Introduction

Best-in-class, robust, bispecific antibody platform technologies developed from proprietary computational modelling and AI-enhanced approaches

Being based on an IgG format, BiXAb® antibodies are endowed with natural drug-like properties and have excellent biophysical and manufacturing properties.

BiXAb’s superior properties

(01)

Speed

Due to the modular “Plug and Play” system for BiXAb® generation, it takes less than a month from in silico Fab sequence identification to BiXAb production and characterization.

(02)

Excellent Pairing

Biomunex has designed proprietary mutations sets (described and covered by a portfolio of different patent families) to ensure a superior pairing between light and heavy chains of the bispecific antibody.

(03)

Linkers

Several proprietary linkers, based on natural human immunoglobulin sequences, have been designed (covered by several patent families), that have sufficient length and flexible rigidity to permit efficient binding (see article published in Frontiers in Immunology by Rabia et al 2023).

(04)

Valency

The BiXAb technology has a tetra-valent architecture which is currently being used in a bispecific, bi-valent format. The tandem Fab-Fab format affords binding properties similar to native monoclonal antibodies and permits avidity-driven binding.

(05)

Excellent Drug-like Properties

The excellent drug-like properties of the BiXAb antibodies are due to the fact that the format is based on a native IgG structure with correctly folded, native Fab structures linked by a natural, immunoglobulin-derived linker sequence. These properties include excellent binding affinities, lack of aggregation and high solubility, low risk of immunogenicity and high thermal stability.

(06)

Robust Manufacturability

Due to the robust biochemical and biophysical features of the “naturally folded” BiXAb structure, excellent manufacturability in CHO cells is achieved with the BiXAb format. This has a major impact on high CMC efficiency, low cost of goods and good clinical supply.

(07)

Strong IP Protection

BIOMUNEX has developed a very strong IP protection position and is continuously solidifying patent protection of its BiXAb technology as well as the innovations and improvements that enable high differentiation of the BiXAb technologies from most of those used in the BsAb field.

Bi- and multi-specific Bixab® antibodies developed by Biomunex

Bi- & Multi-Specific Antibodies

BIOMUNEX discovers and develops new treatments based on disruptive data driven biological approaches in oncology for patients with unmet medical needs, using its bi- and multi-specific antibody technology BiXAb®.

Overall, all BiXAb® programs have demonstrated the superior added value of the BiXAb® technology compared to traditional multi-specific antibodies formats : rapid production, quick generation of the IP covering the molecule, excellent drug-like properties, manufacturability and low COGS (Cost of Goods Sold), and finally versatility and multi-specific capabilities.

Several patent families have been filed to protect such disruptive approaches.